Ulcerative Colitis Clinical Trial
Official title:
The Impact of Circadian Misalignment on Colonic Barrier Homeostasis in Ulcerative Colitis
NCT number | NCT05180279 |
Other study ID # | 19051402 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 1, 2021 |
Est. completion date | June 1, 2024 |
Verified date | June 2024 |
Source | Rush University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to investigate if circadian malalignment (unusual sleeping patterns), such as night shifts (sleeping during the day and being awake during the night time), worsens the inflammation of the gut. We hope to look at patients with Ulcerative Colitis and Healthy Controls.
Status | Completed |
Enrollment | 19 |
Est. completion date | June 1, 2024 |
Est. primary completion date | February 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: UC patients: - M/F, 18-50 y/o - Inactive Disease (Mayo Score = 2) - Stable medications with no disease flares for the > 3 months - Left-sided UC (Montreal E1 or E2) - Normal psychological evaluation and negative drug screen (See Below) Healthy Controls: - M/F, 18-50 y/o, age ± 3y sex, race, and BMI match with UC subject - No clinical evidence of any medical illness - Normal psychological evaluation and negative drug screen (See Below) Exclusion Criteria: UC patients: - Patients with other forms of colitis such as Crohn's disease (CD) or indeterminate colitis - Patient with active UC (Mayo > 2) - Pancolonic UC (colitis past the splenic flexure, Montreal E3)) - Use of biologic or immunomodulatory medications (i.e. Infliximab, Adalimumab, azathioprine, Vedolizumab, methotrexate, etc.) - Gastrointestinal surgery - Other GI diseases or systemic diseases (cardiac, renal failure, cirrhosis) - Shift work in the last 6 months - Antibiotic use within last 12 weeks - Patients who have used anti-diarrheal agents such as Lomotil or Imodium within 3 days of the study - Prednisone use the last 30 days - Significant Depression (score = 14 BDI) - Significant Anxiety (score = 40 STAI) - Use of probiotic supplement in last 4 weeks except yogurt. - Intentional change in diet. - Chronic use of NSAIDS. A washout period of 3 weeks is needed before the subject could be enrolled into the study. Low dose aspirin is allowed. - Chronic Alcohol use. A washout period of 3 weeks is needed before the subject could be enrolled into the study. - Have children under 6 months Healthy Controls: - History of drug abuse, gastrointestinal (GI) surgery, GI diseases, or systemic diseases such as renal (creatinine>1.2 mg/dl), liver, cardiac, or diabetes (Hgb-A1c>8%) - Antibiotic use within last 12 weeks - Shift work in the last 6 months - Use of probiotic supplement except yogurt in last 4 weeks. - Atypical American diet with daily fiber = 16 grams or daily saturated fat = 11 grams by Food Frequency Questionnaire - Chronic use of NSAIDS. A washout period of 3 weeks is needed before the subject could be enrolled into the study. - Chronic Alcohol use. A washout period of 3 weeks is needed before the subject could be enrolled into the study. - Significant Depression (score = 14 BDI) - Significant Anxiety (score = 40 STAI) - Regular use of medications that affect intestinal permeability, intestinal motility and/or endogenous melatonin including metoclopramide, NSAIDs, antibiotics, beta blocker, psychotropic medication, hypnotics and exogenous melatonin products during 4 weeks prior to the study - People who crossed more than 2 time zones in the previous month - Inability to sign an informed consent form. - Have children under 6 months |
Country | Name | City | State |
---|---|---|---|
United States | Rush University Medical Center | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Rush University Medical Center | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Diet | Vioscreen Food Frequency Questionnaire (FFQ). Total of 19 measured food components. Vioscreen captures comprehensive dietary behaviors in just 30 minutes. It is a unique dietary questionnaire, management and analysis system that efficiently gathers and manages data that immediately identifies dietary "habits" and counsel for lifestyle changes. | Once before sleep lab | |
Other | Single day food recall | Automated Self-Administered 24-Hour Recall (ASA24) Dietary Assessment. Total nutrients from all supplements reported in a given day. | Once before sleep lab | |
Other | Chronotype | The Munich ChronoType Questionnaire (MCTQ) uses a self-rated scale to assess individual phase of entrainment on work and work-free days; it is a tool to collect primary sleep times, such as bed- and rise-times, plus the clock time of becoming fully awake as well as sleep latency and inertia, in addition to other time points. | Screening | |
Other | Inflammatory Bowel Disease Questionnaire | 32-item Inflammatory Bowel Disease Questionnaire (IBDQ-32) is the most frequently used instrument to capture disease-specific quality of life in randomized clinical trials for ulcerative colitis | Screening | |
Other | Beck Depression Inventory | The Beck Depression Inventory (BDI, BDI-II), created by Dr. Aaron T. Beck, is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression. | 3 Weeks prior to circadian lab assessments | |
Other | The State-Trait Anxiety Inventory | The State-Trait Anxiety Inventory (STAI) is a commonly used measure of trait and state anxiety | Screening | |
Other | Perceived Stress Questionnaire | Consisting of 30 items, the Perceived Stress Questionnaire was developed as an instrument for assessing the stressful life events and circumstances that tend to trigger or exacerbate disease symptoms. | Screening | |
Other | The International Restless Legs Syndrome Study Group Rating Scale | Subjective scale to measure disease severity of restless legs syndrome in the past week | Screening | |
Other | Berlin Questionnaire | The questionnaire consists of 3 categories related to the risk of having sleep apnea | Screening | |
Other | Pittsburgh Sleep Quality Index | The following questions relate to your usual sleep habits during the past month only. | 3 Weeks prior to circadian lab assessments | |
Primary | Change in the Phase Angle of Entrainment from Baseline (Aligned Circadian Rhythms) to Circadian Misalignment | Phase angle of entrainment is the amount of time between dim light melatonin onset to sleep onset. Melatonin concentration in blood serum is measured by ELISA (enzyme-linked immunosorbent assay). | Blood drawn hourly for eight hours at baseline circadian rhythm (eight draws) and blood drawn hourly for twelve hours at circadian misalignment (12 draws). | |
Primary | Change in Intestinal Permeability from Baseline (Aligned Circadian Rhythms) to Circadian Misalignment | Intestinal permeability is assessed through spectrophotometric measurements of sucralose, sucrose, maltose and lactulose concentrations in urine following ingestion of a sugar cocktail. | 24 hour urine collection beginning at baseline and 24 hour urine collection at circadian misalignment. | |
Secondary | Change in 24 hour Urinary Melatonin Concentrations from Baseline (Aligned Circadian Rhythms) to Circadian Misalignment | Spectrophotometry | 24 hour urine collection at baseline and 24 hour urine collection at circadian misalignment circadian | |
Secondary | Change in Mayo Score from Baseline (Aligned Circadian Rhythms) to Circadian Misalignment | Within the endoscopic component of the Mayo Score, a score of 0 is given for normal mucosa or inactive UC, while a score of 1 is given for mild disease with evidence of mild friability, reduced vascular pattern, and mucosal erythema. | 30 minute flexible sigmoidoscopy at Baseline and 30 minute flexible sigmoidoscopy at Circadian Misalignment | |
Secondary | Change in Stool Calprotectin from Baseline (Aligned Circadian Rhythms) to Circadian Misalignment | Calprotectin is a sensitive marker for inflammation in the gastrointestinal tract. Measured through enzyme linked immunosorbent assay for calprotectin in stool extract. | 10 minute stool collection conducted at baseline circadian rhythm and at circadian misalignment. | |
Secondary | Change in Concentration of Serum Cytokine Markers of Inflammation from Baseline (Aligned Circadian Rhythms) to Circadian Misalignment | Enzyme linked immunosorbent assay | Blood is drawn every two hours over a 24 hour period at baseline (12 draws), and blood is drawn every two hours over a 24 hour period at circadian misalignment | |
Secondary | Changes in Clock Gene Expression in Peripheral Blood Mononuclear Cells from Baseline (Aligned Circadian Rhythms) to Circadian Misalignment | RNA Sequencing | Blood is drawn every two hours over a 24 hour period at baseline (12 draws), and blood is drawn every two hours over a 24 hour period at circadian misalignment | |
Secondary | Changes in Gene Expression of Colonic Tissue Biopsies from Baseline (Aligned Circadian Rhythms) to Circadian Misalignment | Tissue biopsies collected during flexible sigmoidoscopy conducted at Baseline Circadian Rhythm and at Circadian Misalignment. Assessed through histology and RNA Sequencing | 30 minute flexible sigmoidoscopy at Baseline and 30 minute flexible sigmoidoscopy at Circadian Misalignment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |